A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review DOI Creative Commons
Kai Sun, Peng Wang

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 17, 2024

Lung cancer, including small cell lung cancer (SCLC) and non-small (NSCLC), is the most prevalent globally remains leading cause of cancer-related mortality. Epidermal growth factor receptor (EGFR) mutations, frequently observed in female NSCLC patients, have revolutionized treatment strategies with advent tyrosine kinase inhibitors (TKIs). These therapies significantly improve survival are considered standard care for patients harboring EGFR mutations. However, eventually develop resistance to EGFR-TKIs, disease progression. Resistance mechanisms classified as either EGFR-dependent or EGFR-independent, latter involving bypass pathway activation, dysregulation downstream signaling cascades. EGFR-independent often renders all EGFR-TKIs ineffective, necessitating further investigation into mechanisms.

Language: Английский

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer DOI Creative Commons
Jing Zhang, Wenjie Li

BMC Pulmonary Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 6, 2025

While clinical trials have demonstrated enduring responses to amivantamab among advanced non-small cell lung cancer (NSCLC) patients bearing EGFR exon 20 insertion mutations, the associated toxicity profile in real-world scenarios remains elusive. This pharmacovigilance study analyzed data from FDA Adverse Event Reporting System (FAERS) investigate adverse events with over period September 2021 December 2023. A comprehensive disproportionality analysis was performed, employing reporting odds ratio (ROR), proportional (PRR), Empirical Bayes Geometric Mean (EBGM), and Bayesian confidence propagation neural network calculate information components (ICs), identify statistically significant events. proportion of (AEs) attributable injury, poisoning, procedural complications, cutaneous disorders, respiratory ailments, infections, as well vascular lymphatic system disturbances. There were noteworthy incidences AEs including infusion-related reactions, rash, dyspnea, pneumonitis, paronychia, pulmonary embolism, thrombocytopenia, nausea, acneiform dermatitis, deep vein thrombosis, febrile neutropenia, peripheral edema, hypokalemia, neutropenia. Furthermore, majority occurred within first month following initiation treatment, accounting for 51.74% cases. The reversibility amivantamab-related toxicities suggests its promising utility mutations NSCLC.

Language: Английский

Citations

0
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives DOI Open Access
Antonello Veccia,

Mariachiara Dipasquale,

M. Lorenzi

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 668 - 668

Published: Feb. 16, 2025

The treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients was dramatically revolutionized by the introduction EGFR tyrosine kinase inhibitors in clinical practice, both advanced and locally advanced/early stages. present work focuses on osimertinib use early NSCLC Phase 3 trials have supported as new standard care, adjuvant setting disease. ADAURA study reported an overall survival (OS) advantage for completely resected stage II-IIIA EGFR-mutant tumors, while LAURA proved a statistically significant benefit progression-free (PFS) delay central nervous system metastasis development treated with maintenance after concurrent chemoradiotherapy In neoadjuvant setting, data osimertinib’s efficacy are conflicting; therefore, Neo-ADAURA is evaluating safety alone or combination chemotherapy II-IIIB common mutations. We discuss several issues that need to be clarified, such drug uncommon mutations, long-term impact survival, management resistance mechanisms. Moreover, we report studies trying identify potential biomarkers response, circulating tumor DNA (ctDNA), aim selecting who will most from osimertinib.

Language: Английский

Citations

0
Design, Synthesis, and Antitumor Activity Evaluation of Novel 2,4,7-Trisubstituted Quinazoline Derivatives Containing an Aminomethyl Piperidine Moiety DOI

Han Jiahui,

Shihao Wang, Hongjing Chen

et al.

Russian Journal of Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: 51(2), P. 869 - 885

Published: April 1, 2025

Language: Английский

Citations

0
Epinephrine augments the phosphorylation of EGFR and promote the DNA synthesis and migration of cervical cancer cells DOI

Sneha Krishnamoorthy,

Vasudevan Saraswathi,

Muruganantham Bharathi

et al.

3 Biotech, Journal Year: 2025, Volume and Issue: 15(5)

Published: April 14, 2025

Language: Английский

Citations

0
New advances in the treatment of EGFR exon20ins mutant advanced NSCLC DOI

Chun Yuan,

Jun-Yan Yu,

Chuanxiu Zeng

et al.

American Journal of Cancer Research, Journal Year: 2025, Volume and Issue: 15(4), P. 1852 - 1873

Published: Jan. 1, 2025

The epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, albeit less frequent, are a clinically significant subset within the EGFR mutation landscape of non-small cell lung cancer (NSCLC), accounting for roughly 4%-12% all EGFR-altered cases. Ranking as third most prevalent type, these ex20ins mutations trail widely recognized 19 deletion (19-Del) and 21 L858R substitution. In advanced-stage NSCLC patients with conventional treatments such tyrosine kinase inhibitors (TKIs), chemotherapy, immunotherapies often yield suboptimal responses, resulting in unfavorable clinical outcomes. This unmet need underscores urgency to explore innovative targeted therapies. realm precision medicine, agents specifically tailored have emerged promising candidates. review examines latest research on therapies dissecting mechanisms action agents, evaluating results relevant trials, integrating evidence systematic manner. aim is uncover novel therapeutic insights strategies optimize management mutation-positive NSCLC.

Language: Английский

Citations

0
Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis DOI

Yu Tang,

Zhengping Xian,

Fengjiao Wu

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: 398(1), P. 843 - 854

Published: July 29, 2024

Language: Английский

Citations

1
Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway DOI

Xiangdan Cuan,

Yang Xing-ying,

Jinxian Wang

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 153, P. 107808 - 107808

Published: Sept. 7, 2024

Language: Английский

Citations

1
Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations DOI Open Access

Yosuke Maezawa,

Manato Taguchi,

Takeshi Kawakami

et al.

Tuberkuloz ve Toraks, Journal Year: 2024, Volume and Issue: 72(2), P. 107 - 113

Published: June 11, 2024

Investigation of age and smoking in NSCLC patients with uncommon EGFR mutationsIntroduction: In addition to the two common epidermal growth factor receptor (EGFR) mutations, there are many mutations.Due high number types, as well rarity patients, is lack information regarding patient demographics, especially distribution status.Against this background, we conducted an analysis clarify background considering their status. Materials Methods: We retrospectively reviewed medical records non-small cell lung cancer (NSCLC) diagnosed a multicenter clinical practice from 2002 2023. Patients included all cases non-advanced advanced mutations. Results: Information on 158 mutation was collected. Median 72 years, showing that most were 70s. There significant difference between proportion aged up 59 years 75 or older.In 88 habit history, correlation found index age.Among non-smokers, peak ages 70 74, which older than among smokers. Conclusion:Even elderly history smoking, although it unclear whether uncommon, gene testing should be performed possibility these being EGFR-positive.

Language: Английский

Citations

0
Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Key drug screening and mechanism analysis DOI
Qian Tang,

Xuefang Zheng,

Yu Tang

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: July 19, 2024

Abstract In the course of clinical treatment for anti-tumor, combination traditional Chinese medicine (TCM) and other schemes can reduce toxicity increase efficiency. The purpose this paper is to find out key TCM effective components non-small cell lung cancer (NSCLC) analyze its therapeutic mechanism by analyzing prescription combined with chemotherapy NSCLC. Firstly, prescriptions in randomized controlled trials NSCLC were collected, core was screened frequency statistics, association rule analysis cluster analysis. Then, intersection targets potential effects PPI enrichment performed on screen targets, pathways, verified molecular docking experiments. study, 269 among which medication Astragalus membranaceus (HQ, Chinese), Wolfiporia cocos (FL, Atractylodes macrocephala (BZ, Chinese) over 100. Association showed that they highly correlated clustered into same category Their Quercetin, Kaempferol Isorhamnetin. results AKT1 EGFR obtained network could bind stably. KEGG 110 pathways including PI3K-Akt; CCK-8 Isorhamnetin effectively inhibit proliferation A549 cells, had best inhibitory effect. migration invasion induce apoptosis, G1 phase arrest, decrease expression P-PI3K P-AKT cells. a word, include HQ, FL, BZ, etc. Kaempferol, have according research results.

Language: Английский

Citations

0
Design, synthesis, and evaluation of antitumor activity of quinazoline derivatives containing different terminal segments of basic amine groups DOI
Shihao Wang, Zichen Yang, Dayong Gu

et al.

Medicinal Chemistry Research, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 4, 2024

Language: Английский

Citations

0